J
Jolanda Paolini
Researcher at Pfizer
Publications - 32
Citations - 4661
Jolanda Paolini is an academic researcher from Pfizer. The author has contributed to research in topics: Crizotinib & Lung cancer. The author has an hindex of 17, co-authored 29 publications receiving 3972 citations. Previous affiliations of Jolanda Paolini include Kindai University.
Papers
More filters
Journal ArticleDOI
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
Benjamin Solomon,Tony Mok,Dong Wan Kim,Yi-Long Wu,Kazuhiko Nakagawa,Tarek Mekhail,Enriqueta Felip,Federico Cappuzzo,Jolanda Paolini,Tiziana Usari,Shrividya Iyer,Arlene Reisman,Keith D. Wilner,Jennifer M. Tursi,Fiona H Blackhall +14 more
TL;DR: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC and was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life.
Journal ArticleDOI
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin Solomon,Dong Wan Kim,Yi-Long Wu,Kazuhiko Nakagawa,Tarek Mekhail,Enriqueta Felip,Federico Cappuzzo,Jolanda Paolini,Tiziana Usari,Yiyun Tang,Keith D. Wilner,Fiona H Blackhall,Tony Mok +12 more
TL;DR: The final analysis of the PROFILE 1014 study provides a new benchmark for OS in patients with ALK-rearranged non-small-cell lung cancer and highlights the benefit of crizotinib for prolonging survival in this patient population.
Journal ArticleDOI
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
Per Eystein Lønning,J. Geisler,Lars E. Krag,Bjørn Erikstein,Yngve Bremnes,Anne Irene Hagen,Ellen Schlichting,Ernst A. Lien,Erik S. Øfjord,Jolanda Paolini,Anna Polli,Giorgio Massimini +11 more
TL;DR: Exemestane modestly enhanced bone loss from the femoral neck without significant influence on lumbar bone loss, and no major effects on serum lipids, coagulation factors, or homocysteine were recorded.
Journal ArticleDOI
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
Benjamin Solomon,Federico Cappuzzo,Enriqueta Felip,Fiona H Blackhall,Daniel B. Costa,Dong Wan Kim,Kazuhiko Nakagawa,Yi-Long Wu,Tarek Mekhail,Jolanda Paolini,Jennifer M. Tursi,Tiziana Usari,Keith D. Wilner,Paulina Selaru,Tony Mok +14 more
TL;DR: Compared with chemotherapy, crizotinib demonstrated a significantly higher intracranial disease control rate (IC-DCR) in patients with tBM, although sensitivity to detect treatment differences in or between the two subgroups was low.
Journal ArticleDOI
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
Yi-Long Wu,James Chih-Hsin Yang,Dong Wan Kim,Shun Lu,Jianying Zhou,Takashi Seto,Jin Ji Yang,Noboru Yamamoto,Myung-Ju Ahn,Toshiaki Takahashi,Takeharu Yamanaka,Allison Kemner,Debasish Roychowdhury,Jolanda Paolini,Tiziana Usari,Keith D. Wilner,Koichi Goto +16 more
TL;DR: This study demonstrated clinically meaningful benefit and durable responses with crizotinib in East Asian patients with ROS1-positive advanced NSCLC and generally well tolerated, with a safety profile consistent with previous reports.